What it is
CJC-1295 is a GHRH analogue: it tells the pituitary gland to release growth hormone. The DAC part (drug affinity complex) binds it to albumin in the blood, stretching its half-life from minutes to about six to eight days. That is the whole difference from the version without DAC, known as MOD GRF 1-29.
The trade-off
Growth hormone is normally released in pulses. CJC-1295 DAC instead raises the baseline steadily across the week. That is convenient, but less like how the body works on its own, which is why some prefer the short-acting version despite needing more frequent administration.
Two pathways, one pulse
GHRH analogues such as CJC-1295 and ghrelin mimetics such as ipamorelin signal the pituitary through different receptors. Together they produce a considerably larger effect than either alone, which is why they are usually studied as a pair.
- Long-acting GHRH analogue
- Raises growth hormone and IGF-1 across the whole week
- Half-life of about 6 to 8 days
- Complementary to ghrelin mimetics such as ipamorelin
What the evidence tells us.
CJC-1295 is a research peptide. Human clinical data are limited and its long-term safety and effectiveness have not been established. It is not approved by major regulatory agencies for muscle growth, recovery, fat loss or anti-ageing.